Clovis Oncology has decided for now not to implement Kalderos’ 340B Pay service to pay 340B ceiling prices as rebates instead of as discounts.

Clovis Oncology Reverses Decision to Use Kalderos’ 340B Pricing-as-Rebate System

Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late yesterday.

“We can confirm Clovis has decided not to implement our 340B Pay solution at this time, though we continue️ to️ collaborate️ with️ them more broadly,” Kalderos said. “We have other manufacturers interested in moving forward with 340B Pay and remain committed to leveraging our technology to simplify 340B program participation and create greater transparency for all stakeholders.”

Drug manufacturer Clovis Oncology has decided for now not to implement drug discount management company Kalderos’ 340B Pay service to let drug companies pay 340B ceiling prices as back-end rebates instead of as front-end discounts, Kalderos said late yesterday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer